I am an independent investor with more than 15 years of experience researching public companies, with a primary focus on identifying misunderstood businesses where the market’s short-term narrative differs from long-term fundamentals. Before concentrating on biotechnology, I was a long-term investor in Advanced Micro Devices (NASDAQ: AMD) during its multi-year turnaround and Maxar Technologies (NYSE: MAXR) prior to its acquisition. Those investments reinforced my conviction that meaningful returns often come from understanding the underlying business, competitive positioning, and long-term catalysts rather than reacting to short-term market sentiment. Over the past seven years, my research has become increasingly focused on small- and micro-cap biotechnology companies, particularly those developing novel therapies for oncology and hematologic malignancies. My investment process centers on fundamental research, including SEC filings, ClinicalTrials.gov records, FDA regulatory pathways, peer-reviewed scientific literature, conference presentations, and corporate communications. I also seek to understand clinical trial design, survival statistics, regulatory strategy, and the competitive landscape surrounding emerging therapies. One company I have followed extensively is SELLAS Life Sciences, where I have been a shareholder for more than seven years. My research has included reviewing publicly available regulatory filings, analyzing clinical trial developments, engaging with management through shareholder communications, and participating in discussions with independent AML specialists to better understand the evolving treatment landscape. While SELLAS has become one of my deepest research projects, my broader interests include immunotherapy, precision medicine, targeted oncology, and event-driven biotechnology investing. Professionally, I am the founder and owner of Mobilize Cloud, a digital consulting and software development firm based in Ohio. My career in technology has been built around solving complex problems, analyzing data, and developing practical solutions for businesses. Those same analytical skills have naturally shaped my investment philosophy: question assumptions, rely on primary sources whenever possible, and distinguish evidence from narrative. I do not claim to predict clinical trial outcomes or possess information beyond what is publicly available. Instead, my goal is to synthesize complex scientific, regulatory, and financial information into clear, well-supported research that helps investors better understand both the opportunities and the risks associated with innovative biotechnology companies. Through my writing, I hope to encourage thoughtful, evidence-based discussion around biotechnology and other sectors where deep research can uncover opportunities that may not be fully reflected in prevailing market sentiment. Whether the topic is biotechnology, technology turnarounds, or other event-driven investments, my objective is to help readers evaluate the facts, challenge conventional assumptions, and make more informed investment decisions.
SELLAS: Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn’t Caught Up
